Section
The DAPARHT trial demonstrates that dapagliflozin improves kidney function slope over 12 months in heart transplant recipients, offering a promising renal protective strategy without additional safety risks.
Living donor transplantation demonstrates overall positive mental health outcomes but reveals high-risk subgroups necessitating improved psychosocial assessments and tailored follow-up care to optimize donor wellbeing.
This review synthesizes evidence from the Prepare for Kidney Care trial and complementary studies, highlighting that in older frail or multimorbid kidney failure patients, responsive management offers similar quality-adjusted life expectanc
Using organs from Trypanosoma cruzi-positive donors expands transplant availability in endemic regions but necessitates vigilant monitoring to manage Chagas disease reactivation safely.
This article reviews the development and preliminary evaluation of a novel toolkit designed to facilitate patient-centered decision-making in end-stage kidney disease, improving the implementation of the KDOQI End-Stage Kidney Disease Life
Serial monitoring of donor-derived cell-free DNA during the first 4 months post-kidney transplantation reveals distinct risk profiles for rejection, graft dysfunction, and loss, enabling early stratification and potentially guiding personal
This national cohort study reveals that intravenous albumin administration after outpatient paracentesis significantly reduces hospitalization rates for acute kidney injury, especially in cirrhotic patients with impaired renal function.
A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.
Cardiovascular risk prediction models show limited accuracy in postmenopausal women with chronic kidney disease, often underestimating risk, highlighting the need for improved tools in this high-risk population.
This study evaluates semaglutide’s benefits over dulaglutide or liraglutide among diabetic hemodialysis patients, highlighting improved survival, reduced hospitalizations, and greater weight loss with semaglutide.
Recent large-cohort analyses reveal that donor hospital distance from OPO headquarters does not increase deceased donor kidney nonuse, while policy changes like KAS250 temporarily raise nonuse rates but overall kidney utilization continues
An innovative, ultra-low-cost normothermic machine perfusion (NMP) system was developed and validated, enabling extended organ preservation and in vivo function in porcine and human tissues, offering affordable platforms for research and th
The phase 3 VISIONARY trial establishes sibeprenlimab as a promising therapy in IgA nephropathy, significantly stabilizing eGFR decline and reducing kidney-function deterioration over 24 months with a favorable safety profile.
Interim analysis of a phase 3 trial demonstrates povetacicept’s efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.
Ravulizumab, a terminal complement C5 inhibitor, significantly reduces proteinuria in adults with IgA nephropathy, demonstrating safety and biomarker improvements in phase 2 and 3 trials, highlighting its therapeutic potential.
Raman spectroscopy-based urine molecular fingerprinting offers a promising non-invasive biomarker to predict delayed graft function, assess baseline kidney allograft quality, and monitor transplant health postoperatively in patients receivi
A new OPTN policy removing race from eGFR calculations shows promise in increasing kidney transplantation access for Black patients by adding waiting time credits, while not disadvantaging others on the waitlist.
A novel nomogram using pretransplant triglycerides and body weight shows promise to guide early mycophenolate mofetil dosing after kidney transplantation, potentially reducing drug overexposure before therapeutic drug monitoring is feasible
This randomized trial compared intermittent hemodialysis and continuous renal-replacement therapy in critically ill AKI patients and found that continuous therapy was associated with lower 90-day mortality and similar kidney outcomes.
A randomized clinical trial demonstrates that adding intraoperative dobutamine to norepinephrine during surgical source control for septic shock significantly decreases postoperative acute kidney injury incidence and severity.
